This trial will test whether psilocybin is a safe and effective treatment for major depressive disorder and borderline personality disorder.
2 Primary · 2 Secondary · Reporting Duration: Week 2 to Week 5
Experimental Treatment
10 Total Participants · 1 Treatment Group
Primary Treatment: Psilocybin · No Placebo Group · Phase 2
Age 18 - 65 · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Illinois | 34.9% |
Indiana | 6.0% |
California | 4.8% |
Other | 54.2% |
18 - 65 | 98.8% |
65+ | 1.2% |
University of Chicago | 100.0% |
Met criteria | 89.0% |
Did not meet criteria | 11.0% |
0 | 50.0% |
3+ | 50.0% |
100.0% | |